262 related articles for article (PubMed ID: 20088891)
1. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
2. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
[TBL] [Abstract][Full Text] [Related]
3. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
[TBL] [Abstract][Full Text] [Related]
4. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
5. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
[TBL] [Abstract][Full Text] [Related]
7. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
[TBL] [Abstract][Full Text] [Related]
8. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
9. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
[TBL] [Abstract][Full Text] [Related]
10. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
11. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
12. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment.
Derbala MF; Amer AM; Almohanadi M; John A; Amin A; John A; Sharma M; Alkaabi SR; Al Dweik NZ; Pasic F; Yaqoob R; Butt MT; Shebl FM
J Viral Hepat; 2011 Jul; 18(7):e258-62. PubMed ID: 21108700
[TBL] [Abstract][Full Text] [Related]
14. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
[TBL] [Abstract][Full Text] [Related]
15. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
[TBL] [Abstract][Full Text] [Related]
16. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
17. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
[TBL] [Abstract][Full Text] [Related]
18. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
19. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
20. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Núñez M; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de Los Santos I; San Joaquín I; Echeverría S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola JM; Romero M; García-Samaniego J; Soriano V;
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):972-82. PubMed ID: 17725413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
